GB0117583D0 — Novel compounds
Assigned to AstraZeneca AB · Expires 2001-09-12 · 25y expired
What this patent protects
The invention relates to a compound of formula (1) in which Q is -CO- or -C(R<SUP>4</SUP>)(R<SUP>5</SUP>)-, where R<SUP>4 </SUP>is a hydrogen atom or C<SUB>1-4</SUB>alkyl and R<SUP>5 </SUP>is a hydrogen atom or hydroxy g…
USPTO Abstract
The invention relates to a compound of formula (1) in which Q is -CO- or -C(R<SUP>4</SUP>)(R<SUP>5</SUP>)-, where R<SUP>4 </SUP>is a hydrogen atom or C<SUB>1-4</SUB>alkyl and R<SUP>5 </SUP>is a hydrogen atom or hydroxy group; and Ar is a 5- to 10-membered aromatic ring system where up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.